Latest news with #CerusCorporation
Business Wire
a day ago
- Business
- Business Wire
Cerus Corporation to Participate in the Goldman Sachs 46 th Annual Global Healthcare Conference 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46 th Annual Global Healthcare Conference 2025 in Miami, Florida, on Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time. A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus' Investor Relations website at A replay of the webcast will be available on Cerus Investor Relations website shortly after the event for 30 days. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Business Wire
28-05-2025
- Business
- Business Wire
Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product Safety (ANSM) and the other by the Swiss Agency for Therapeutic Products (Swissmedic). The INT200, the Company's next generation LED-based illumination device, was developed as the new foundational platform for the INTERCEPT Blood System, with input and feedback from global customers to enhance daily blood center operations. The contemporary vertical configuration is designed to improve workflow and ergonomics while freeing up bench space (three INT200 illumination devices can fit in the same footprint as a single INT100). In addition to the vertical configuration, the INT200 features touch screen navigation and intuitive software, improved tray design, intelligent scanning, and custom reporting. These in-country regulatory approvals follow the CE Mark authorization received in March. In France and Switzerland, all platelet components have been treated with the INTERCEPT Blood System since 2018 and 2011, respectively. 'We are pleased with the important in-country approvals in France and Switzerland and view these approvals as an important validation of our technology,' said Vivek Jayaraman, Cerus' chief operating officer. 'We have started the commercial rollout of this next generation platform and the early feedback continues to be very encouraging. France and Switzerland continue to be at the forefront of blood transfusion safety and we value their partnership toward ensuring the safety of the blood supply in their respective countries.' The Company expects to convert its installed base of INT100s in EMEA to INT200s over the next three years. The Company continues to plan for additional regulatory submissions, including a planned PMA submission to the FDA during 2026, as well as future innovation of the INTERCEPT platelet and plasma systems to leverage the INT200 platform. Further information about the INT200 can be found at ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the Company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. Forward-Looking Statements Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus' products, prospects and expected results, including statements relating to: Cerus' expectations regarding the conversion of INT100s to INT200s and the timing thereof; Cerus' plans for future regulatory submissions and the timing thereof; Cerus' plans for future product innovations; and other statements that are not historical fact. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System, including the risks that Cerus may not (a) effectively commercialize the INT200, (b) realize meaningful revenue contribution from the INT200 in the near term or at all and/or (c) effectively expand its commercialization activities into additional geographies; risks associated with macroeconomic developments, including ongoing military conflict in Ukraine, new or increased tariffs and escalating trade tensions and the resulting global economic and financial disruptions, and the current and potential future negative impacts to Cerus' business operations; risks related to Cerus' ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction and the INTERCEPT Blood System is safe, effective and economical; risks related to the uncertain and time-consuming development and regulatory process, including the risk that Cerus may be unable to obtain and maintain the requisite in-country regulatory approvals necessary to commercialize the INT200 in a timely manner or at all; risks related to product safety; risks related to adverse market and economic conditions, including continued or more severe adverse fluctuations in foreign exchange rates and/or continued or more severe weakening in economic conditions resulting from military conflicts, rising interest rates, inflation, new or increased tariffs and escalating trade tensions or otherwise in the markets where Cerus is anticipated to commercialize the INT200; risks associated with Cerus' ability to maintain an effective, secure manufacturing supply chain, including the risks that (a) Cerus' supply chain could be negatively impacted as a result of the evolving impact of macroeconomic developments, including the ongoing military conflict in Ukraine, rising interest rates, inflation, and new or increased tariffs and escalating trade tensions, (b) Cerus' manufacturers could be unable to comply with extensive regulatory agency requirements, and (c) Cerus may be unable to maintain its supply agreements with its third party suppliers; risks associated with Cerus' need for additional funding; risks associated with the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for Cerus to produce, market and distribute the INT200; as well as other risks detailed in Cerus' filings with the Securities and Exchange Commission, including under the heading 'Risk Factors' in Cerus' Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 1, 2025. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.
Yahoo
24-05-2025
- Business
- Yahoo
When Should You Buy Cerus Corporation (NASDAQ:CERS)?
While Cerus Corporation (NASDAQ:CERS) might not have the largest market cap around , it received a lot of attention from a substantial price movement on the NASDAQGM over the last few months, increasing to US$1.86 at one point, and dropping to the lows of US$1.22. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Cerus' current trading price of US$1.25 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Cerus's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. According to our valuation model, Cerus seems to be fairly priced at around 11% below our intrinsic value, which means if you buy Cerus today, you'd be paying a fair price for it. And if you believe that the stock is really worth $1.40, then there's not much of an upside to gain from mispricing. So, is there another chance to buy low in the future? Given that Cerus's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us an opportunity to buy later on. This is based on its high beta, which is a good indicator for share price volatility. See our latest analysis for Cerus Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. With profit expected to grow by a double-digit 12% in the upcoming year, the short-term outlook is positive for Cerus. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation. Are you a shareholder? CERS's optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven't considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value? Are you a potential investor? If you've been keeping tabs on CERS, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it's worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example, we've discovered 2 warning signs that you should run your eye over to get a better picture of Cerus. If you are no longer interested in Cerus, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
24-05-2025
- Business
- Yahoo
When Should You Buy Cerus Corporation (NASDAQ:CERS)?
While Cerus Corporation (NASDAQ:CERS) might not have the largest market cap around , it received a lot of attention from a substantial price movement on the NASDAQGM over the last few months, increasing to US$1.86 at one point, and dropping to the lows of US$1.22. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Cerus' current trading price of US$1.25 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Cerus's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. According to our valuation model, Cerus seems to be fairly priced at around 11% below our intrinsic value, which means if you buy Cerus today, you'd be paying a fair price for it. And if you believe that the stock is really worth $1.40, then there's not much of an upside to gain from mispricing. So, is there another chance to buy low in the future? Given that Cerus's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us an opportunity to buy later on. This is based on its high beta, which is a good indicator for share price volatility. See our latest analysis for Cerus Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. With profit expected to grow by a double-digit 12% in the upcoming year, the short-term outlook is positive for Cerus. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation. Are you a shareholder? CERS's optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven't considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value? Are you a potential investor? If you've been keeping tabs on CERS, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it's worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example, we've discovered 2 warning signs that you should run your eye over to get a better picture of Cerus. If you are no longer interested in Cerus, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-03-2025
- Business
- Yahoo
Cerus Leads Our Selection Of 3 Promising Penny Stocks
As U.S. stocks attempt to recover from recent downturns, with the S&P 500 and Nasdaq aiming to end their losing streaks, investors are navigating a market filled with uncertainty yet ripe with potential opportunities. Penny stocks, though often overlooked in favor of more established names, remain an intriguing investment area for those seeking growth in smaller or newer companies. By focusing on firms with strong financial foundations and clear paths to growth, investors can uncover promising prospects within this niche segment of the market. Name Share Price Market Cap Financial Health Rating Safe Bulkers (NYSE:SB) $3.82 $403.65M ★★★★☆☆ Tuya (NYSE:TUYA) $3.57 $2.28B ★★★★★★ Peraso (NasdaqCM:PRSO) $0.8062 $2.92M ★★★★★☆ Sensus Healthcare (NasdaqCM:SRTS) $4.74 $78.85M ★★★★★★ Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $67.38M ★★★★★★ TETRA Technologies (NYSE:TTI) $3.41 $454.11M ★★★★☆☆ Imperial Petroleum (NasdaqCM:IMPP) $2.59 $77.35M ★★★★★★ BAB (OTCPK:BABB) $0.84 $6.03M ★★★★★★ QuantaSing Group (NasdaqGM:QSG) $3.08 $136.47M ★★★★★★ CBAK Energy Technology (NasdaqCM:CBAT) $0.8281 $76.45M ★★★★★☆ Click here to see the full list of 765 stocks from our US Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Cerus Corporation is a biomedical products company with a market cap of $284.26 million. Operations: The company generates revenue from its Blood Safety segment, amounting to $180.27 million. Market Cap: $284.26M Cerus Corporation, with a market cap of US$284.26 million, is noteworthy in the penny stock space for its stable revenue stream from the Blood Safety segment, totaling US$180.27 million. Despite being unprofitable with a net loss of US$20.92 million in 2024, it has reduced losses significantly over five years and maintains a satisfactory net debt to equity ratio of 6.5%. The company's short-term assets exceed both short and long-term liabilities, providing financial stability amidst its growth trajectory forecasted at 12.28% annually. However, significant insider selling may warrant caution for potential investors. Navigate through the intricacies of Cerus with our comprehensive balance sheet health report here. Examine Cerus' earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Navitas Semiconductor Corporation designs, develops, and markets gallium nitride power integrated circuits and related technologies for power conversion and charging, with a market cap of approximately $482.04 million. Operations: Navitas Semiconductor Corporation does not report specific revenue segments. Market Cap: $482.04M Navitas Semiconductor, with a market cap of US$482.04 million, is gaining attention due to its recent breakthrough in GaN technology, which could revolutionize power conversion across multiple sectors such as EV charging and solar inverters. Despite being unprofitable with a net loss of US$84.6 million in 2024, the company maintains financial stability through sufficient cash reserves and no debt obligations. Recent announcements include a US$50 million equity offering and product advancements that target high-growth markets. However, its volatile share price and ongoing losses highlight potential risks for investors considering this penny stock opportunity. Dive into the specifics of Navitas Semiconductor here with our thorough balance sheet health report. Learn about Navitas Semiconductor's future growth trajectory here. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Riskified Ltd. develops and provides an e-commerce risk management platform for online merchants to build trusted consumer relationships across various regions, with a market cap of approximately $755.07 million. Operations: The company generates its revenue from the Security Software & Services segment, totaling $327.52 million. Market Cap: $755.07M Riskified Ltd., with a market cap of US$755.07 million, presents both opportunities and challenges as a penny stock. The company has demonstrated revenue growth, reporting US$327.52 million in 2024, yet remains unprofitable with net losses shrinking over the years. Recent strategic moves include share buybacks totaling US$75 million and partnerships aimed at enhancing fraud prevention capabilities through AI-driven solutions like Adaptive Checkout. Despite its unprofitability, Riskified's strong cash position covers liabilities comfortably and supports operations for over three years without debt reliance. However, ongoing losses and potential sale rumors underscore inherent investment risks in this space. Unlock comprehensive insights into our analysis of Riskified stock in this financial health report. Evaluate Riskified's prospects by accessing our earnings growth report. Gain an insight into the universe of 765 US Penny Stocks by clicking here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CERS NasdaqGM:NVTS and NYSE:RSKD. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
